China Expands Medical Insurance Coverage to Include Assisted Reproductive Technology in 19 Regions
BEIJING—As of September 1, 2024, a total of 19 provinces, municipalities, and the Xinjiang Production...
2024
BioAge Labs Taps Former GSK CEO Jean-Pierre Garnier as Chairman
NEW YORK—BioAge Labs, a US-based biotechnology company specializing in anti-aging therapies, has announced the appointment...
China’s NMPA Suspends Dr. Reddy’s Atomoxetine Imports Amid Quality Concerns
BEIJING—The National Medical Products Administration (NMPA) has issued a notification to immediately suspend the import,...
Roche Diagnostics to Double Down on China with RMB 3 Billion Suzhou Plant Expansion
SUZHOU—Roche Diagnostics, the Swiss healthcare giant, has entered into a new investment agreement with the...
WuXi Biologics to Acquire Full Control of Vaccine Contract Services Subsidiary for $108.5 Million
HONG KONG—WuXi Biologics (HKG: 2269), a leading global open biopharmaceutical technology platform company, has announced...
Tiantan Biological to Acquire Wuhan Zhongyuan Ruide for $185 Million, Expanding Plasma Resources
BEIJING—Beijing Tiantan Biological Products Co., Ltd (Tiantan Biological, SHA: 600161) has announced that its subsidiary,...
Junshi Biosciences Logs 17.37% Revenue Growth in 2024H1, Fueled by Loqtorzi Sales Surge
SHANGHAI—Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced its financial results for...
MicroPort Medical Reports 17% Revenue Growth in 2024H1, Driven by Subsidiaries’ Performance
HONG KONG—MicroPort Medical Science and Technology Co., Ltd (HKG: 0853), a leading medical device company,...
Sino Medical Sciences Secures Hong Kong Approval for Coronary Balloon Dilation Catheter
HONG KONG—Sino Medical Sciences Technology Inc., (SHA: 688108), a leading medical device company based in...
Hutchmed Withdraws Fruquintinib’s New Indication Application in China, Seeks Alternative Regulatory Path
HONG KONG—Hutchmed (HKG: 0013) has announced its decision to proactively withdraw the new indication application...
J&J Files NDA for FcRn Blocker Nipocalimab, Targets Myasthenia Gravis Market
US-based Johnson & Johnson (NYSE: JNJ) has made a global first New Drug Application (NDA)...
Merck Ends Phase III Keytruda Studies in NSCLC and cSCC Due to Insufficient Results
US-based Merck, Sharp & Dohme Inc. (NYSE: MRK) announced the discontinuation of two Phase III...
BioMarin to Cut 225 Jobs Amid Challenges in Gene Therapy Commercialization
US-based BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is navigating a challenging period marked by difficulties in...
MicroPort CardioFlow to Acquire RMB 380 Million Shanghai Assets for Global HQ Expansion
China-based MicroPort Scientific Corp. (HKG: 0853) has announced that its spin-off, MicroPort CardioFlow Medtech Co.,...
Tonghua Golden-Horse, UCB Seek China Approvals for Alzheimer’s, Myasthenia Gravis Drugs
China’s Tonghua Golden-Horse Pharmaceutical Industry Co. Ltd. and Belgium-based UCB (FRA: UNC) are seeking marketing...
Dizal Pharmaceutical’s Financial Turnaround Continues with 33% Net Loss Reduction in H1 2024
Dizal Pharmaceutical Co., Ltd, a pharmaceutical entity listed in Shanghai (SHA: 688192), has unveiled its...
Doma Biopharmaceutical Receives FDA Clearance for Phase I Trial of EGFR-MET Targeting ADC, DM005
Doma Biopharmaceutical (Suzhou) Co., Ltd, a Chinese pharmaceutical firm, has received approval from the U.S....
Jiyuan Biotechnology’s Stem Cell Therapy for Type 2 Diabetes Gains NMPA Tacit Approval for Clinical Trials
BEIJING—Jiyuan Biotechnology, a leading Chinese biopharmaceutical company, has secured tacit clinical trial approval from the...
AstraZeneca Boosts Investment in Qingdao Aerosol Production Hub to $750 Million
QINGDAO—AstraZeneca (NASDAQ: AZN), a leading UK-based pharmaceutical company, has announced a further investment in its...
NMPA Suspends Jeisys Medical Inc.’s Nd:YAG Laser Equipment Over Quality Concerns
BEIJING—The National Medical Products Administration (NMPA) of China has issued a notification to immediately suspend...